STUDY(Year)  Hips       Mean Follow Up (years) Pain Relief (%) ROM HO (%)/ SHO (%)/ Reankylosis (%) Survivorship Revisions (n)
Bisla [14] 34 4 91 148 62/26/6          - 2
Resnick [21] 21 3 NS NS 57/43/29          - None
Williams [22] 86 3 NS NS 55/11/7          - 10
Baldurson [23] 18 3.8 94 90FL 28/0/None          - None
Shahnahan [24] 16 7.4 94 NS 100/36/None          - 1
Finterbrush [25] 35 7.5 NS 86FL 17/NS/None          - 5
Walker [13] 29 4.8 97 168 77/23/15          - None
Gulateri [26] 73 7.5 89 NS NS/21/None          - None
Sochart [27] 43 23 100 185 14/0/None 92% at 10y; 72%at 20y; 70%at 30y 12
Tang [10] 46 16.5 94 NS 74/24/None 100% at 5y; 98% at 10y; 66% at 15y 17
Lehtimaki [28] 76 NS NS NS NS 80% at 10y; 66% at 15y; 62% at 20y 3
Joshi [29] 181 10 96 NS 12/0/ None 87% at 10y; 81% at15y; 72%at 27y 25
Range of movement expressed as either an arc of flexion (FL) or a total cumulative range (ROM) HO Heterotropic Ossification; SHO significant HO- Brooker Class 3 and 4 -Survivorship analysis not performed using the Kaplan Meier technique NS Not specified
Table 1: Review of total hip arthroplasty for ankylosing spondylitis (cemented)